ClinicalTrials.gg
Active, not recruitingNCT06942910ZODIACUpdated Sep 2, 2026

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

A Phase 2 interventional study of Zibotentan/Dapagliflozin and Dapagliflozin in Chronic Kidney Disease With High Proteinuria, sponsored by AstraZeneca. Active, not recruiting at 14 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Kidney Diseases by AstraZeneca — none open to participants now, 3 under way, 2 of them phase 3. Kidney Diseases · AstraZeneca.

Started
2025
the only one that year
Phase 2
2 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Kidney Diseases by AstraZeneca, this one is the only one that started in 2025, is one of 2 in phase 2, and was the 11th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

None of the 11 studies in Kidney Diseases by AstraZeneca is open now. The open studies under Kidney Diseases, anywhere →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Kidney Diseases by AstraZeneca as a file.
02

Study summary

A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria

Read the detailed description

This is a Phase II, multicentre, randomised, double-blind, active-controlled, 2-arm parallel group study to evaluate the efficacy, safety, and tolerability of zibotentan and dapagliflozin in FDC compared to dapagliflozin alone, given QD on top of SoC, in adult participants with CKD and high proteinuria, with or without T2DM.

Participants who are not already on SGLT2i at screening will receive a 28 day run in intervention with SGLT2i (dapagliflozin) QD. All participants will undergo a 12-week double-blind period. At the end of the treatment visit, participants will discontinue the blinded study intervention and begin open-label dapagliflozin monotherapy until the conclusion of the 4-week safety follow-up period.

The results of this study will provide clinical data on efficacy and safety of an innovation treatment in the new region (the Russian Federation), which will be an important additional data source for Zibotentan/Dapagliflozin FDC approval process in the Eurasian Economic Union.

03

Conditions studied

  • Chronic Kidney Disease With High Proteinuria

Browse trials for

Keywords

  • Zibotentan
  • Nephrology
  • Dapagliflozin
  • Sodium-glucose co-transporter 2
  • sodium-glucose co-transporter 2 inhibitor
  • Kidney diseases
  • Endothelin antagonist
  • High Proteinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age at the time of signing the .
  • Diagnosis of CKD with ≥ 20 and \< 90 mL/min/1.73m2 AND UACR > 700 mg/g (> 79 mg/mmol) or UPCR > 1000 mg/g (> 113 mg/mmol).
  • (BMI) within the range ≤40 kg/m2.
  • Female participants must be either - not of or - women of childbearing potential (WOCBP) using at least one highly effective method for at least 3 months prior to first dose of study intervention.
  • All WOCBP must have a negative serum pregnancy test result at screening.
  • Receiving RAASi therapy (ACEi or ARB), and for the patient maximum tolerated labelled daily dose, that has been stable for at least 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • , unstable, or uncontrolled medical condition which in the Investigator's opinion makes it undesirable for the participant to participate in the study.
  • Known to dapagliflozin or zibotentan or any of the of the product. History or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i therapy or ERAs.
  • class III or class IV HF.
  • Participants hospitalised for HF and/or who have not been stable on HF therapy during the last 6 months prior to screening.
  • HF due to cardiomyopathies that would primarily require other specific treatment.
  • High output HF (eg, due to hyperthyroidism or Paget's disease).
  • HF due to primary cardiac valvular disease/dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
  • Evidence of rales or jugular venous distention on physical examination.
  • Type 1 diabetes mellitus.
  • History of any life-threatening ventricular dysrhythmia (continuous or paroxysmal).
  • Participants hospitalised for heart disease or cardiac procedures or for COVID-19 during the last 3 months prior to screening.
  • History of solid organ transplantation or bone marrow transplant.
  • Any condition with a of less than 1 year based on investigator´s clinical judgment.
  • within the past 5 years. Exceptions to this criterion include non-melanoma skin cancer and curatively treated cervical carcinoma in situ.
  • Significant liver disease as judged by the investigator.
  • Renal replacement therapy or previous kidney transplant.
  • Known history of significant drug or alcohol abuse within 12 months of screening.
  • On treatment with strong or moderate inducer.
  • On systemic therapy other than prespecified stable maintenance therapy.
  • Participants treated or expecting to be treated with tolvaptan (including as part of participation in a clinical trial), any other ERAs, or budesonide (where used to treat IBD or IgAN).
  • Systolic blood pressure above 160 mmHg and/or below 90 mmHg.
  • Significant impairment of liver function defined as or ALT >3 x (ULN) or Total serum >2 x ULN (an isolated increase in bilirubin in participants with known Gilbert's syndrome is not a reason for exclusion).
  • NT-proBNP ≥ 600 pg/mL (or NT-proBNP ≥ 1200 pg/mL, if associated with atrial fibrillation) measured by local laboratory at screening.
  • Any of the following results of echocardiography at screening:

    • (LVEF) \< 50%
    • significant ventricular wall motion abnormality or severe cardiac valve abnormalities
    • isolated pulmonary arterial hypertension (as defined by local clinical practice) or right ventricular failure; in the absence of left-sided HF
  • Women who are pregnant, breast-feeding, or women with intent of getting pregnant.
  • Women who are not willing to use adequate or cannot, in the opinion of the Investigator, understand and/or comply with the study requirements regarding contraception.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Zibotentan/Dapagliflozin dose A or Zibotentan/Dapagliflozin dose B

    Drug dose is determined based on eGFR values. Participants will receive daily oral dose of zibotentan/dapagliflozin in fixed dose combination.

    Drug: Zibotentan/Dapagliflozin

  • Active comparator
    Dapagliflozin alone

    Participants will receive daily oral dose of dapagliflozin.

    Drug: Dapagliflozin

Interventions

  • DrugZibotentan/Dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

  • Participants will receive monotherapy dapagliflozin as per the arms they are randomized to

06

What researchers measure

Primary outcomes

  1. Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline

    To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing albuminuria

    Time frame: At Week 12

Secondary outcomes

  1. Change in log-transformed Urinary Protein to Creatinine Ratio (UPCR) from baseline

    To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing proteinuria

    Time frame: At Week 12

  2. Change in systolic and diastolic blood pressure (BP) from baseline

    To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing systolic and diastolic BP

    Time frame: At Week 12

  3. Number of participants experiencing adverse events

    To assess the safety and tolerability of treatment with zibotentan and dapagliflozin in FDC compared to dapagliflozin alone during 12 weeks of treatment and 4 weeks of safety follow-up

    Time frame: From Week 1 (Day 1) until Follow-up visit (Week 18, Day 112)

Other outcomes

  1. Change in estimated Glomerular Filtration Rate (eGFR) from baseline

    To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to slow decline in kidney function, as measured by eGFR

    Time frame: At Week 12

  2. Proportion of participants achieving Urine Protein to Creatinine Ratio (UPCR) < 1000 mg/g and > 30% reduction from baseline

    To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to reduce proteinuria, as measured by the proportion of participants achieving UPCR \< 1000 mg/g and \> 30% reduction from baseline

    Time frame: Across the visits from Week 2 (Day 14) up to Week 12 (Day 84)

  3. Proportion of participants achieving Urinary Albumin to Creatinine Ratio (UACR) < 300 mg/g

    To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to reduce albuminuria, as measured by the proportion of participants achieving UACR \< 300 mg/g

    Time frame: Across the visits from Week 2 (Day 14) up to Week 12 (Day 84)

07

Study locations

14 sites
  • Research Site
    Aramil, 624002, Russia
  • Research Site
    Izhevsk, 426061, Russia
  • Research Site
    Krasnoyarsk, 660062, Russia
  • Research Site
    Moscow, 111539, Russia
  • Research Site
    Moscow, 117036, Russia
  • Research Site
    Moscow, 129327, Russia
  • Research Site
    Omsk, 644112, Russia
  • Research Site
    Orenburg, 460018, Russia
  • Research Site
    Perm, 614000, Russia
  • Research Site
    Saint Petersburg, 195067, Russia
  • Research Site
    Saratov, 410053, Russia
  • Research Site
    Saratov, 410054, Russia
  • Research Site
    Ulyanovsk, 432009, Russia
  • Research Site
    Yaroslavl, 150062, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at : https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 16 months after the start.

Of 41 phase 2 interventional studies under Kidney Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartActual
May 7, 2025
Primary completionEst.
Sep 26, 2026
CompletionEst.
Sep 26, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942910
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
May 7, 2025
Primary completion
Sep 26, 2026 (estimated)
Completion
Sep 26, 2026 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion